126 related articles for article (PubMed ID: 28333918)
1. 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013.
Lynch JA; Berse B; Coomer N; Kautter J
Genet Med; 2017 Oct; 19(10):1134-1143. PubMed ID: 28333918
[TBL] [Abstract][Full Text] [Related]
2. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
3. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
4. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
Wilson LE; Pollack CE; Greiner MA; Dinan MA
Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
[TBL] [Abstract][Full Text] [Related]
5. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
[TBL] [Abstract][Full Text] [Related]
6. Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
Lynch JA; Berse B; Rabb M; Mosquin P; Chew R; West SL; Coomer N; Becker D; Kautter J
BMC Cancer; 2018 Mar; 18(1):306. PubMed ID: 29554880
[TBL] [Abstract][Full Text] [Related]
7. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Orucevic A; Heidel RE; Bell JL
Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
[TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.
Hull LE; Lynch JA; Berse BB; DuVall SL; Chun DS; Venne VL; Efimova OV; Icardi MS; Kelley MJ
Clin Breast Cancer; 2018 Apr; 18(2):135-143. PubMed ID: 29306660
[TBL] [Abstract][Full Text] [Related]
9. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
Su KW; Hall J; Soulos PR; Abu-Khalaf MM; Evans SB; Mougalian SS; Rutter CE; Davidoff AJ; Gross CP
J Geriatr Oncol; 2016 Jan; 7(1):15-23. PubMed ID: 26704661
[TBL] [Abstract][Full Text] [Related]
10. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
[TBL] [Abstract][Full Text] [Related]
11. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
[TBL] [Abstract][Full Text] [Related]
12. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
[TBL] [Abstract][Full Text] [Related]
13. Implementation of the 21-gene recurrence score test in the United States in 2011.
Lynch JA; Berse B; Petkov V; Filipski K; Zhou Y; Khoury MJ; Hassett M; Freedman AN
Genet Med; 2016 Oct; 18(10):982-90. PubMed ID: 26890451
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA; Wilson LE; Reed SD
J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
[TBL] [Abstract][Full Text] [Related]
15. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jasem J; Amini A; Rabinovitch R; Borges VF; Elias A; Fisher CM; Kabos P
J Clin Oncol; 2016 Jun; 34(17):1995-2002. PubMed ID: 27001563
[TBL] [Abstract][Full Text] [Related]
16. Factors Influencing Receipt of Interventional Pain Management Among Medicaid Beneficiaries with Cancer.
Halpern MT; Fiero MH
Pain Physician; 2019 May; 22(3):E147-E155. PubMed ID: 31151338
[TBL] [Abstract][Full Text] [Related]
17. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
[No Abstract] [Full Text] [Related]
18. Breast cancer multigene testing trends and impact on chemotherapy use.
Ray GT; Mandelblatt J; Habel LA; Ramsey S; Kushi LH; Li Y; Lieu TA
Am J Manag Care; 2016 May; 22(5):e153-60. PubMed ID: 27266581
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
Casasanta N; Kipnis ST; Linville L; Lipinski S; Knoedler A; Marino A; McHenry A; Biagi T; Stark E; Amdur R; Denduluri N; Rodriguez P; Isaacs C; Kaltman R
Clin Breast Cancer; 2020 Apr; 20(2):125-130. PubMed ID: 31526714
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
